Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-Chlorodeoxyadenosine in haematological malignancies

S Castaigne1

  • 1Service d'Hématologie Adulte, Hôpital Saint-Louis, Paris, France.

Nouvelle Revue Francaise D'Hematologie
|February 1, 1993
PubMed
Summary

Hereditary adenosine deaminase deficiency impairs lymphocyte development due to deoxyadenosine buildup. 2-chlorodeoxyadenosine (2CdA) effectively treats certain leukemias and lymphomas with low toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Leukemia·2016
Same author

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML.

Bone marrow transplantation·2012
Same author

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.

Leukemia·2012
Same author

False positive galactomannan Platelia due to piperacillin-tazobactam.

Medecine et maladies infectieuses·2011
Same author

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia.

Leukemia·2011
Same author

Recurrent in-frame insertion in C/EBPalpha TAD2 region is a polymorphism without prognostic value in AML.

Leukemia·2007

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Hereditary adenosine deaminase deficiency disrupts lymphocyte development.
  • Accumulation of deoxyadenosine nucleotides is the underlying mechanism.
  • 2-chlorodeoxyadenosine (2CdA) is resistant to adenosine deaminase and accumulates intracellularly.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of 2-chlorodeoxyadenosine (2CdA) in treating specific hematological malignancies.
  • To explore 2CdA as a therapeutic agent for cancers resistant to standard treatments.

Main Methods:

  • Administration of 2CdA at a dose of 0.1 mg/kg/day for seven days.
  • Clinical observation of patient response and toxicity.

Main Results:

  • 2CdA demonstrated low toxicity at the tested dosage.
  • Significant efficacy was observed in patients with hairy cell leukemia, chronic lymphocytic leukemia, low-grade lymphoma, and acute myeloid leukemia.

Conclusions:

  • 2-chlorodeoxyadenosine (2CdA) is a promising therapeutic agent for various hematological malignancies.
  • The drug's efficacy and low toxicity profile warrant further investigation in clinical settings.

Related Experiment Videos